NFE2L2 and cancer: We also compare results obtained for KDMD5 and AURKB overexpression/knockdown with an established positive marker for cancer stemness (SRY-Box transcription factor 2 or SOX2), cisplatin resistance (Cyclins D1) and diapause (NRF2) as shown in Supplementary Figure S1.